AbbVie and Cugene partner to tackle autoimmune diseases
AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The Chicago-based pharma firm, AbbVie, received the option […]
AbbVie and Cugene have teamed up to research autoimmune diseases and cancer in an exclusive worldwide agreement. The Chicago-based pharma firm, AbbVie, received the option […]
AbbVie’s would-be blockbuster Rinvoq has notched up another positive trial in Crohn’s disease, showing that it can achieve clinical remission over a full year when […]
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma’s rival antibody tralokinumab. […]
Shots: The approval is based on the P-III clinical trial program including Measure Up 1/2/AD Up that evaluates the efficacy & safety of Rinvoq (15/30 […]
Shots: Study 2 of the P-III SELECT-AXIS 2 clinical trial evaluates the efficacy & safety of upadacitinib (qd, 15mg) vs PBO in 314 adults with […]
The FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings for the drugs as well as others […]
The FDA may be reluctant to trust JAK inhibitors, but the European Commission is more willing, and has just handed a first-in-class approval in atopic […]
Shots: The approval is based on 3 P-III studies i.e., Measure Up 1/2/AD Up evaluating the efficacy & safety of Rinvoq (15/30 mg, qd) as […]
Shots: The approval is based on data from two P-III studies i.e SELECT-PsA 1 & 2 evaluating the safety & efficacy of Rinvoq vs PBO […]
Shots: The P-III SELECT-COMPARE study evaluates the safety and efficacy of Rinvoq (15 mg, qd) vs PBO and Humira (SC, 40mg, every other week) in […]
The FDA has said it will wait for additional results from last week’s trial showing an increased risk of cardiac side effects with Pfizer’s arthritis […]
JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. […]
JAK inhibitor Xeljanz is one of Pfizer’s top-selling drugs, despite a ‘black box’ warning for blood clots and cancers added to its label in 2019. […]
Shots: The approval is based on data from three pivotal clinical trials P-II SELECT-PsA 1& 2 and P-II/III SELECT-AXIS 1 involves assessing of Rinvoq in […]
Shots: The company submitted applications to the US FDA & EMA seeking approval for Rinvoq (upadacitinib) for adults (15mg/30mg, qd) and adolescents (15mg, qd) with […]
Shots: The P-III AD Up study involves assessing Rinvoq (15/30mg) + TCS vs PBO + TCS in patients (aged≥12) with the mod. to sev. AD […]
Shots: The P-III Measure Up 2 study involves assessing of Rinvoq (15/30mg) vs PBO in adults and adolescents aged 12-18yrs. or older with mod. to […]
Copyright © 2024 | WordPress Theme by MH Themes